MTTP and APOCIII are responsible for the assembly, formation, and release of VLDL from the hepatocytes and are regulated by the FOXOa1 and can contribute to hepatic steatosis, so we checked their gene expression and we saw a decreased level of both in the hepatocytes of the compound-treated group (Figure 17). Here, MT-TP is linked to fatty liver disease.